163 related articles for article (PubMed ID: 17167037)
21. Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1.
Liao HX; Tsao CY; Alam SM; Muldoon M; Vandergrift N; Ma BJ; Lu X; Sutherland LL; Scearce RM; Bowman C; Parks R; Chen H; Blinn JH; Lapedes A; Watson S; Xia SM; Foulger A; Hahn BH; Shaw GM; Swanstrom R; Montefiori DC; Gao F; Haynes BF; Korber B
J Virol; 2013 Apr; 87(8):4185-201. PubMed ID: 23365441
[TBL] [Abstract][Full Text] [Related]
22. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates.
Stamatatos L; Lim M; Cheng-Mayer C
AIDS Res Hum Retroviruses; 2000 Jul; 16(10):981-94. PubMed ID: 10890360
[TBL] [Abstract][Full Text] [Related]
23. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys.
Seaman MS; Xu L; Beaudry K; Martin KL; Beddall MH; Miura A; Sambor A; Chakrabarti BK; Huang Y; Bailer R; Koup RA; Mascola JR; Nabel GJ; Letvin NL
J Virol; 2005 Mar; 79(5):2956-63. PubMed ID: 15709015
[TBL] [Abstract][Full Text] [Related]
24. Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies.
Ma BJ; Alam SM; Go EP; Lu X; Desaire H; Tomaras GD; Bowman C; Sutherland LL; Scearce RM; Santra S; Letvin NL; Kepler TB; Liao HX; Haynes BF
PLoS Pathog; 2011 Sep; 7(9):e1002200. PubMed ID: 21909262
[TBL] [Abstract][Full Text] [Related]
25. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
[TBL] [Abstract][Full Text] [Related]
26. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.
Krachmarov CP; Honnen WJ; Kayman SC; Gorny MK; Zolla-Pazner S; Pinter A
J Virol; 2006 Jul; 80(14):7127-35. PubMed ID: 16809318
[TBL] [Abstract][Full Text] [Related]
27. TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice.
Godot V; Tcherakian C; Gil L; Cervera-Marzal I; Li G; Cheng L; Ortonne N; Lelièvre JD; Pantaleo G; Fenwick C; Centlivre M; Mouquet H; Cardinaud S; Zurawski SM; Zurawski G; Milpied P; Su L; Lévy Y
PLoS Pathog; 2020 Nov; 16(11):e1009025. PubMed ID: 33253297
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity testing of a novel engineered HIV-1 envelope gp140 DNA vaccine construct.
Kumar S; Yan J; Muthumani K; Ramanathan MP; Yoon H; Pavlakis GN; Felber BK; Sidhu M; Boyer JD; Weiner DB
DNA Cell Biol; 2006 Jul; 25(7):383-92. PubMed ID: 16848679
[TBL] [Abstract][Full Text] [Related]
29. Production and characterization of mouse monoclonal antibodies against the transmembrane protein of a human immunodeficiency virus type 2.
Komatsu H; Yamashita A; Tozawa H; Mizutani Y; Honda M; Kawamura M; Hayami M
AIDS Res Hum Retroviruses; 1991 Dec; 7(12):999-1005. PubMed ID: 1725959
[TBL] [Abstract][Full Text] [Related]
30. Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens.
Seaman MS; Leblanc DF; Grandpre LE; Bartman MT; Montefiori DC; Letvin NL; Mascola JR
Virology; 2007 Oct; 367(1):175-86. PubMed ID: 17599382
[TBL] [Abstract][Full Text] [Related]
31. Characterization of monoclonal antibodies to human immunodeficiency virus type 1 gp41 by HIV-1 polypeptides expressed in Escherichia coli.
Larcher C; Bröker M; Huemer HP; Sölder B; Schulz TF; Hofbauer JM; Wachter H; Dierich MP
FEMS Microbiol Immunol; 1990 Sep; 2(2):103-10. PubMed ID: 1701654
[TBL] [Abstract][Full Text] [Related]
32. Characterization of a novel human anti-HIV-1 gp41 IgM monoclonal antibody designated clone 37.
Cao C; Bai Y; Holloway MJ; Edgeworth RL; Jackson EA; Cotropia J; Ugen KE
DNA Cell Biol; 2004 Dec; 23(12):836-41. PubMed ID: 15684710
[TBL] [Abstract][Full Text] [Related]
33. Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Easterhoff D; Bradley T; Luo K; Williams WB; Liao HX; Moody MA; Phad GE; Vázquez Bernat N; Melillo B; Santra S; Smith AB; Karlsson Hedestam GB; Haynes B; Sodroski J
J Virol; 2016 May; 90(10):5031-5046. PubMed ID: 26962221
[TBL] [Abstract][Full Text] [Related]
34. Characterization of a stable HIV-1 B/C recombinant, soluble, and trimeric envelope glycoprotein (Env) highly resistant to CD4-induced conformational changes.
Kumar R; Ozorowski G; Kumar V; Holden LG; Shrivastava T; Patil S; Deshpande S; Ward AB; Bhattacharya J
J Biol Chem; 2017 Sep; 292(38):15849-15858. PubMed ID: 28743743
[TBL] [Abstract][Full Text] [Related]
35. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
Bower JF; Li Y; Wyatt R; Ross TM
Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
[TBL] [Abstract][Full Text] [Related]
36. Envelope sequence variability and serologic characterization of HIV type 1 group O isolates from equatorial guinea.
Hunt JC; Golden AM; Lund JK; Gürtler LG; Zekeng L; Obiang J; Kaptué L; Hampl H; Vallari A; Devare SG
AIDS Res Hum Retroviruses; 1997 Aug; 13(12):995-1005. PubMed ID: 9264286
[TBL] [Abstract][Full Text] [Related]
37. Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein.
Hicar MD; Chen X; Sulli C; Barnes T; Goodman J; Sojar H; Briney B; Willis J; Chukwuma VU; Kalams SA; Doranz BJ; Spearman P; Crowe JE
PLoS One; 2016; 11(7):e0158861. PubMed ID: 27411063
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
[TBL] [Abstract][Full Text] [Related]
39. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.
Stamatos NM; Mascola JR; Kalyanaraman VS; Louder MK; Frampton LM; Birx DL; VanCott TC
J Virol; 1998 Dec; 72(12):9656-67. PubMed ID: 9811699
[TBL] [Abstract][Full Text] [Related]
40. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
